According to filings with the U.S. Securities and Exchange Commission, Alzheon is raising up to $49,995,798.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Martin Tolar played a key role in securing the recent investment.

About Alzheon
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimers clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimers patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com .

To learn more about Alzheon, visit http://alzheon.com/

Contact:
Martin Tolar, President and Chief Executive Officer
508-861-7709
https://www.linkedin.com/in/martintolar/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.